// App-Quantinova.ai

P090 : Protocol for the two-cohort, open-label, single-arm EMERALD study of emapalumab, an anti-interferon gamma monoclonal antibody, in patients with macrophage activation syndrome in rheumatic diseases

Researchers

Presenter

  • Paul Brogan

Principal Investigators

  • Alexei Grom

  • Radmila Kanceva

  • Fabrizio De Benedetti

Medical Centers

  • Division of Rheumatology, Ospedale Pediatrico Bambino Gesù IRCCS, Roma, Roma, Italy

  • University College London Great Ormond Street Institute of Child Health, Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom

  • Division of Rheumatology, Cincinnati Children's Hospital, Cincinnati, OH

  • Department of Cancer Biology, University of Cincinnati College of Medicine, Cincinnati, OH

  • Clinical Operations, Swedish Orphan Biovitrum AG (Sobi), Basel, Switzerland

Locations

  • Italy

  • United States

  • United Kingdom

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

Disease

  • Macrophage activation syndrome

Biomarkers

  • N/A

Drug/Treatment

  • Interferon Gamma

  • NI0501

  • Interferon

Outcome

  • N/A

Study Design

  • Open Label

  • Single Arm

  • Multicenteric

  • Cohort

Phase

  • II/III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved